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As the Journal Matures
This is the 36th issue of JACC: Cardiovascular Interventions and, as such, it has reached a
egree of maturity as a resource for investigators to publish their important research findings
nd for practitioners of cardiovascular medicine to keep abreast of these advances in the field.
his was my response when I was asked for my “elevator speech” describing what the journal
s about. If the elevator ride were 1 floor more, I would add that it is truly an international
ournal. (Elevator or lift? We do get many papers from the United Kingdom.) The
nternational contributions to the success of the journal were brought to my attention even
ore acutely at the recent EuroPCR meeting in Paris.
EuroPCR, as I indicated in this column last year, is a very large and highly organized
nternational symposium that again was extremely successful in its educational goals. It differs
ainly in form from the American College of Cardiology (ACC) and Transcatheter
ardiovascular Therapeutics (TCT) symposia, since industry-sponsored educational sessions
re still possible outside of the United States. I would add that their sessions were without any
ndustry control, and I detected no bias in presentations. Of course, the subject matter was of
nterest to the sponsoring industry. The debate about industry involvement in education is an
mportant one but not for this limited space.
For us (the journal), there were 2 highlights at the EuroPCR. First, we were invited to
articipate in a joint JACC: Cardiovascular Interventions/EuroInterventions symposium on
ublishing. I chaired this session with Patrick Serruys, and the presentations on preparing
apers, statistical methods, impact factor, reviewing papers, and the future of publishing were
ell received by an overflow audience. This is the kind of collaboration that I think is helpful
or authors, reviewers, and editors alike to improve medical publishing. I hope similar sessions
ill be held at the major cardiovascular conferences.
We also took advantage of the venue in Paris to hold an editorial board meeting, and we
nvited board members and frequent authors to provide input for improvement of the journal.
e were joined by Anthony DeMaria, Editor-in-Chief of JACC, and a lively discussion
nsued. Board meetings are traditionally combined JACC, JACC: Cardiovascular Interventions,
nd JACC: Cardiovascular Imaging, but this meeting was more intimate and focused on
nterventions. Perhaps we will repeat these types of gatherings at future interventional
onferences. The meeting gave us a chance to present the state of the journal statistics to a
roup of major contributors to the journal who were attending EuroPCR. We presented them
he following facts about the journal. The circulation is now greater than 11,000, which is a
7% increase from last year. Submissions continue to rise: 441 (2008), 663 (2009), 737 (2010),
nd now 300 in the first four months of 2011. The largest number of submissions in 2010
ame from the United States (39%), but the next 10 leading contributors were Italy, Japan, the
etherlands, Canada, Germany, United Kingdom, Spain, France, Korea, and India and Israel
ied. In 2010, publications were: 122 new research, 36 editorial comments, 12 state-of-the-art
apers, and 18 Images in Intervention. Focused issue subjects since inception have included the
ollowing topics: platelet responsiveness, stent technology, stent strut coverage, systems of care for
cute myocardial infarction, transradial approach, second-generation drug-eluting stents, chronic
otal occlusion, percutaneous coronary intervention for unprotected left main disease, transcatheter
ortic valve implantation (TAVI), long-term outcomes for drug-eluting stents, outcomes for ST-
egment elevation myocardial infarction, and new directions for platelet inhibition. Contributors to
he journal include: 1,265 authors, 603 reviewers, and 100 editorial comment authors. In addition,
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829there are 40 online interviews of authors conducted by the
editors. At the meeting in Paris, we discussed where the
journal is going, especially in the near future for online
publishing and the app for JACC: Cardiovascular
nterventions and JACC: Cardiovascular Imaging on the iPad.
Some very high quality congenital heart disease and
peripheral vascular disease papers are in press. As we look
forward to the release of the impact factor for the journal at
the end of June, we anticipate even more interest and must
prepare to cope with our page limitations. The current
acceptance rate for research papers is only 16%, and in order
to be able to publish the quality papers submitted, more
pages might be necessary. Several positive suggestions came
from those attending the board meeting and reception, and
we welcome suggestions from readers as well.
One other activity for the journal was an exhibit
sponsored by the ACC and TCT highlighting thecollaboration of the 2 organizations in the fall (TCT
venue) and spring (ACC venue) major interventional
meetings in the United States. Finally, a prominent
feature of the EuroPCR was the continuing experience
and investigation of TAVI. Note that in this issue, there
are several papers on TAVI that were the subject of
significant discussion at the meeting in Paris. All of you
who have contributed to the growth and maturity of this
journal should be proud.
Address correspondence to:
Spencer B. King III, MD, MACC
Editor-in-Chief, JACC: Cardiovascular Interventions
Saint Joseph’s Heart and Vascular Institute
5665 Peachtree Dunwoody Road, NE
Atlanta, Georgia 30342
sbking@sjha.org
